Cervical Cancer Pipeline Insight 2025: 70+ Emerging Therapies Targeting HPV-Driven Tumorigenesis | DelveInsight

DelveInsight's "Cervical Cancer - Pipeline Insight, 2025" provides an in-depth assessment of the rapidly evolving therapeutic landscape for cervical cancer, a malignancy predominantly driven by persistent infection with high-risk human papillomavirus (HPV) strains. Despite progress in screening and vaccination, cervical cancer continues to pose a significant global health burden, particularly in low- and middle-income countries.

Therapeutic development has expanded beyond traditional chemotherapy and radiation approaches. The pipeline is now enriched with over 70+ novel therapies, spanning immunotherapies, antibody-drug conjugates (ADCs), targeted agents, vaccines, and gene therapies. These candidates aim to overcome resistance mechanisms, target HPV oncoproteins (E6/E7), and address unmet needs in recurrent or metastatic settings.

Checkpoint inhibitors (e.g., anti-PD-1/PD-L1 agents) are a major area of focus, with several trials exploring combinations with anti-angiogenics, radiotherapy, or therapeutic vaccines. Tisotumab vedotin (a tissue factor-directed ADC) and other next-gen ADCs are showing promise in advanced settings, with ongoing Phase II/III evaluations.

Therapeutic vaccines aimed at clearing HPV-infected cells or enhancing cellular immunity are also prominent in the pipeline, both as standalone therapies and in combination regimens. Additionally, gene-modulating approaches using CRISPR or siRNA are under investigation for their potential to disrupt HPV-driven oncogenesis at the genomic level.

As the understanding of HPV-host interactions deepens and precision medicine tools mature, the cervical cancer drug development space is poised for major breakthroughs. With robust R&D momentum from over 70+ active companies globally, the therapeutic pipeline holds the potential to redefine cervical cancer treatment across all stages-from localized disease to advanced metastatic forms.

Interested in learning more about the current treatment landscape and the key drivers shaping the cervical cancer pipeline? Click here: https://www.delveinsight.com/report-store/cervical-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Cervical Cancer Pipeline Report
• DelveInsight's cervical cancer pipeline analysis depicts a strong space with 70+ active players working to develop 70+ pipeline drugs for cervical cancer treatment.
• The leading cervical cancer companies Regeneron Pharmaceuticals, Jiangsu Hengrui Medicine, Akeso Biopharma, Celgene/MedImmune, Henlix Biotech, Zeria, Advaxis, AnGes, Advenchen Laboratories/Jiangsu Chia Tai Tianqing Pharmaceutical, Valent recombinant vaccine - National Vaccine and Serum Institute, Xiamen Innovax Biotech, Genentech, Bristol-Myers Squibb, Ono Pharmaceuticals, InnoMab, BeiGene, Agenus/Ludwig Institute for Cancer Research, EMD Serono, Merck, Apollomics, Immunitor, Arcus Biosciences, Guangzhou Gloria Biosciences, Taiho Pharmaceutical, Innovent Biologics, Clovis Oncology, Janssen, GlaxoSmithKline, Iovance Biotherapeutics, and others are evaluating their lead assets to improve the cervical cancer treatment landscape.
• Key cervical cancer pipeline therapies in various stages of development include Cemiplimab, Camrelizumab, AK-104, Durvalumab, HLX10, Serplulimab, Z 100, Axalimogene filolisbac, Cadonilimab, Human papillomavirus vaccine, Catequentinib, Atezolizumab, Human papillomavirus recombinant vaccine nonavalent, Nivolumab, Nimotuzumab, Tislelizumab, Balstilimab, Bintrafusp alfa, Geptanolimab, Cervical cancer vaccine, Tiragolumab, Zimberelimab, Ipilimumab biosimilar, Rucaparib, Niraparib, Autologous tumour infiltrating lymphocytes, and others.
• In July 2025, Merck (MSD outside the US and Canada) announced Health Canada's approval of KEYTRUDA® (pembrolizumab) combined with chemoradiotherapy for treating FIGO 2014 Stage III-IVA cervical cancer. This approval is based on Phase 3 KEYNOTE-A18 trial results showing significant improvements in progression-free and overall survival compared to chemoradiotherapy alone.
• In May 2025, Teal Health® announced FDA approval of the Teal WandTM, the first at-home self-collection device for cervical cancer screening in the U.S. Designed for women aged 25-65 at average risk, the prescription device offers a convenient, comfortable, and clinically accurate alternative to in-office Pap smears. The at-home kit includes telehealth support, with medical providers overseeing prescriptions, results, and patient care.
• In April 2025, Biocon Biologics received FDA approval for JobevneTM (bevacizumab-nwgd), a biosimilar to Avastin®, for intravenous use. Jobevne is approved for multiple cancers, including metastatic colorectal cancer, non-squamous non-small cell lung cancer, recurrent glioblastoma, metastatic renal cell carcinoma, advanced cervical cancer, and ovarian, fallopian tube, or primary peritoneal cancer.

Request a sample and discover the recent breakthroughs happening in the cervical cancer pipeline landscape at https://www.delveinsight.com/report-store/cervical-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Cervical Cancer Overview
Cervical cancer arises from the uncontrolled growth of abnormal cells in the cervix, the lower part of the uterus that connects to the vagina. It is primarily caused by persistent infection with high-risk types of human papillomavirus (HPV), a common sexually transmitted virus. Early stages of cervical cancer often show no symptoms, but as the disease progresses, symptoms may include abnormal vaginal bleeding, pelvic pain, and pain during intercourse.

Screening through Pap smears and HPV testing has significantly reduced cervical cancer rates by detecting precancerous changes early. Treatment depends on the stage and may involve surgery, radiation therapy, chemotherapy, or a combination. Vaccination against HPV is a key preventive measure that can greatly reduce the risk of developing cervical cancer.

Find out more about cervical cancer medication at https://www.delveinsight.com/report-store/cervical-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Cervical Cancer Treatment Analysis: Drug Profile
Axalimogene filolisbac: Advaxis
Axalimogene filolisbac is a cancer vaccine designed as an immunotherapy targeting HPV-associated cancers, including cervical cancer. It works by activating the body's immune system to recognize and attack cancer cells. Administered intravenously, it is being developed for patients with persistent, recurrent, or metastatic squamous or non-squamous cervical cancer who have progressed after first-line therapy. If approved, it would provide a new treatment option for this patient group. The Phase III AIM2CERV study is evaluating ADXS11-001 (Axalimogene filolisbac) as an adjuvant treatment following chemoradiation in high-risk, locally advanced cervical cancer.

Camrelizumab: Jiangsu Hengrui Medicine Co., Ltd.
Camrelizumab (AiRuiKaTM) is a PD-1 inhibitor developed by Jiangsu Hengrui Medicine Co., Ltd., which recently received conditional approval in China for relapsed or refractory classical Hodgkin lymphoma. It is also being tested in various cancers such as B cell lymphoma, esophageal squamous cell carcinoma, gastric and gastroesophageal junction cancer, hepatocellular carcinoma, nasopharyngeal cancer, and non-squamous non-small cell lung cancer. Currently, Camrelizumab is in Phase III clinical trials for cervical cancer treatment.

AK104 (Cadonilimab): Akeso
Cadonilimab (AK104) is a novel, first-in-class bi-specific antibody targeting PD-1 and CTLA-4, developed by Akeso. It is being investigated for multiple cancers including liver, cervical, lung, gastric, esophageal squamous cell carcinoma, and nasopharyngeal carcinoma. Preliminary data indicate that Cadonilimab offers lower toxicity and promising safety and efficacy compared to combined PD-1 and CTLA-4 therapies. In September 2020, China's National Medical Products Administration (NMPA) accepted the new drug application for Cadonilimab as a treatment for relapsed or metastatic cervical cancer, granting it priority review.

Learn more about the novel and emerging cervical cancer pipeline therapies at https://www.delveinsight.com/report-store/cervical-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Cervical Cancer Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

By Molecule Type
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Scope of the Cervical Cancer Pipeline Report
• Coverage: Global
• Key Cervical Cancer Companies: Regeneron Pharmaceuticals, Jiangsu Hengrui Medicine, Akeso Biopharma, Celgene/MedImmune, Henlix Biotech, Zeria, Advaxis, AnGes, Advenchen Laboratories/Jiangsu Chia Tai Tianqing Pharmaceutical, Valent recombinant vaccine - National Vaccine and Serum Institute, Xiamen Innovax Biotech, Genentech, Bristol-Myers Squibb, Ono Pharmaceuticals, InnoMab, BeiGene, Agenus/Ludwig Institute for Cancer Research, EMD Serono, Merck, Apollomics, Immunitor, Arcus Biosciences, Guangzhou Gloria Biosciences, Taiho Pharmaceutical, Innovent Biologics, Clovis Oncology, Janssen, GlaxoSmithKline, Iovance Biotherapeutics, and others.
• Key Cervical Cancer Pipeline Therapies: Cemiplimab, Camrelizumab, AK-104, Durvalumab, HLX10, Serplulimab, Z 100, Axalimogene filolisbac, Cadonilimab, Human papillomavirus vaccine, Catequentinib, Atezolizumab, Human papillomavirus recombinant vaccine nonavalent, Nivolumab, Nimotuzumab, Tislelizumab, Balstilimab, Bintrafusp alfa, Geptanolimab, Cervical cancer vaccine, Tiragolumab, Zimberelimab, Ipilimumab biosimilar, Rucaparib, Niraparib, Autologous tumour infiltrating lymphocytes, and others.

To dive deep into rich insights for drugs used for cervical cancer treatment, visit: https://www.delveinsight.com/report-store/cervical-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Cervical Cancer Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Cervical Cancer Pipeline Therapeutics
6. Cervical Cancer Pipeline: Late-Stage Products (Phase III)
7. Cervical Cancer Pipeline: Mid-Stage Products (Phase II)
8. Cervical Cancer Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.